JP2010522208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522208A5 JP2010522208A5 JP2009554753A JP2009554753A JP2010522208A5 JP 2010522208 A5 JP2010522208 A5 JP 2010522208A5 JP 2009554753 A JP2009554753 A JP 2009554753A JP 2009554753 A JP2009554753 A JP 2009554753A JP 2010522208 A5 JP2010522208 A5 JP 2010522208A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- liquid formulation
- imc
- polysorbate
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 8
- 239000007788 liquid Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 3
- 229940068968 Polysorbate 80 Drugs 0.000 claims 3
- 102000004965 antibodies Human genes 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000007979 citrate buffer Substances 0.000 claims 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 239000011778 trisodium citrate Substances 0.000 claims 1
Claims (8)
- IMC−A12抗体、5mM〜50mMの濃度のクエン酸塩緩衝液、75mM〜150mMの濃度のグリシン、75〜150mMの濃度のNaClおよび0.001%〜1.0%(重量/体積)の濃度のポリソルベート80を含んでなり、pHが6.0〜6.5の範囲にある、液体処方物。
- IMC−A12抗体の濃度が5mg/mL〜30mg/mLである、請求項1に記載の液体処方物。
- クエン酸塩緩衝液の濃度が10mMである、請求項1に記載の液体処方物。
- グリシンの濃度が100mMである、請求項1に記載の液体処方物。
- NaClの濃度が100mMである、請求項1に記載の液体処方物。
- ポリソルベート80の濃度が0.01%(重量/体積)である、請求項1に記載の液体処方物。
- pHが6.5である、請求項1に記載の液体処方物。
- 5mg/mLのIMC−A12抗体、10mMのクエン酸ナトリウム緩衝液、100mMのグリシン、100mMのNaClおよび0.01%(重量/体積)のポリソルベート80を含んでなり、pHが6.5である、請求項1に記載の液体処方物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91974407P | 2007-03-22 | 2007-03-22 | |
PCT/US2008/057718 WO2008116103A2 (en) | 2007-03-22 | 2008-03-20 | Stable antibody formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010522208A JP2010522208A (ja) | 2010-07-01 |
JP2010522208A5 true JP2010522208A5 (ja) | 2011-04-28 |
Family
ID=39766776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009554753A Pending JP2010522208A (ja) | 2007-03-22 | 2008-03-20 | 安定な抗体処方物 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100260766A1 (ja) |
EP (1) | EP2136839A4 (ja) |
JP (1) | JP2010522208A (ja) |
KR (1) | KR20090113340A (ja) |
CN (1) | CN101668540A (ja) |
AU (1) | AU2008228823A1 (ja) |
BR (1) | BRPI0809112A2 (ja) |
CA (1) | CA2681743A1 (ja) |
CR (1) | CR11005A (ja) |
DO (1) | DOP2009000222A (ja) |
EA (1) | EA200970880A1 (ja) |
EC (1) | ECSP099642A (ja) |
IL (1) | IL200321A0 (ja) |
MX (1) | MX2009010179A (ja) |
TN (1) | TN2009000382A1 (ja) |
UA (1) | UA96473C2 (ja) |
WO (1) | WO2008116103A2 (ja) |
ZA (1) | ZA200905636B (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
TW200838559A (en) * | 2006-11-29 | 2008-10-01 | Imclone Systems Inc | Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity |
PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
EP2346900A1 (en) | 2008-10-29 | 2011-07-27 | Wyeth LLC | Methods for purification of single domain antigen binding molecules |
CN102271707B (zh) | 2008-10-29 | 2015-04-08 | 阿布林克斯公司 | 单域抗原结合性分子的制剂 |
CN102438652B (zh) * | 2008-11-12 | 2014-08-13 | 米迪缪尼有限公司 | 抗体制剂 |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
SI2376116T1 (sl) | 2008-12-12 | 2016-03-31 | Boehringer Ingelheim International Gmbh | Anti-IGF protitelesa |
TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
MX351706B (es) * | 2010-09-17 | 2017-10-25 | Baxalta Inc | Estabilizacion de inmunoglobulinas a traves de una formulacion acuosa con histidina a ph acido debil a neutro. |
CN103189074A (zh) | 2010-11-05 | 2013-07-03 | 诺华有限公司 | 使用il-17拮抗剂治疗类风湿性关节炎的方法 |
WO2012151199A1 (en) | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
US10634589B2 (en) * | 2011-10-26 | 2020-04-28 | Amgen Inc. | Methods of reducing or eliminating protein modification and degradation arising from exposure to UV light |
ES2669395T3 (es) | 2011-10-28 | 2018-05-25 | Prothena Biosciences Limited | Anticuerpos humanizados que reconocen la alfa-sinucleína |
RU2642262C2 (ru) | 2012-01-27 | 2018-01-24 | Протена Биосайенсис Лимитед | Гуманизированные антитела, которые распознают альфа-синуклеин |
AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
RU2015130613A (ru) | 2012-12-26 | 2017-01-31 | Вокхардт Лимитед | Фармацевтическая композиция |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
RS63210B1 (sr) | 2015-11-03 | 2022-06-30 | Janssen Biotech Inc | Potkožne formulacije anti-cd38 antitela i njihova upotreba |
JP6992262B2 (ja) * | 2016-03-31 | 2022-02-15 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
JP4124480B2 (ja) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
PT1324776E (pt) * | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
PT2087908T (pt) * | 2001-06-26 | 2018-07-16 | Amgen Inc | Anticorpos contra opgl |
MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
AU2003211990A1 (en) * | 2002-02-14 | 2003-09-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution pharmaceuticals |
KR20050109489A (ko) * | 2003-02-13 | 2005-11-21 | 화이자 프로덕츠 인크. | 항-인슐린양 성장인자 i 수용체 항체의 용도 |
ES2527871T3 (es) * | 2003-05-01 | 2015-02-02 | Imclone Llc | Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana |
US7579157B2 (en) * | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
EA200600234A1 (ru) * | 2003-08-13 | 2006-08-25 | Пфайзер Продактс Инк. | Модифицированные igf - 1r антитела человека |
CA2607663C (en) * | 2005-05-19 | 2014-08-12 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
MX2007016306A (es) * | 2005-06-15 | 2008-03-07 | Schering Corp | Formulaciones de anticuerpo anti-igf1r. |
KR20080104160A (ko) * | 2006-03-28 | 2008-12-01 | 에프. 호프만-라 로슈 아게 | 항-igf-1r 인간 단일클론 항체 제형 |
-
2008
- 2008-03-20 KR KR1020097019642A patent/KR20090113340A/ko active IP Right Grant
- 2008-03-20 BR BRPI0809112-9A patent/BRPI0809112A2/pt not_active IP Right Cessation
- 2008-03-20 EP EP08744136A patent/EP2136839A4/en not_active Withdrawn
- 2008-03-20 CA CA002681743A patent/CA2681743A1/en not_active Abandoned
- 2008-03-20 MX MX2009010179A patent/MX2009010179A/es not_active Application Discontinuation
- 2008-03-20 JP JP2009554753A patent/JP2010522208A/ja active Pending
- 2008-03-20 WO PCT/US2008/057718 patent/WO2008116103A2/en active Application Filing
- 2008-03-20 EA EA200970880A patent/EA200970880A1/ru unknown
- 2008-03-20 UA UAA200909552A patent/UA96473C2/ru unknown
- 2008-03-20 CN CN200880009446A patent/CN101668540A/zh active Pending
- 2008-03-20 US US12/528,882 patent/US20100260766A1/en not_active Abandoned
- 2008-03-20 AU AU2008228823A patent/AU2008228823A1/en not_active Abandoned
-
2009
- 2009-08-10 IL IL200321A patent/IL200321A0/en unknown
- 2009-08-13 ZA ZA200905636A patent/ZA200905636B/xx unknown
- 2009-08-28 CR CR11005A patent/CR11005A/es not_active Application Discontinuation
- 2009-09-18 TN TNP2009000382A patent/TN2009000382A1/fr unknown
- 2009-09-18 DO DO2009000222A patent/DOP2009000222A/es unknown
- 2009-09-21 EC EC2009009642A patent/ECSP099642A/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010522208A5 (ja) | ||
JP2010529999A5 (ja) | ||
JP2011088913A5 (ja) | ||
AR124140A2 (es) | Formulaciones de anticuerpos | |
JP2016513069A5 (ja) | ||
NZ595526A (en) | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant | |
UA96473C2 (ru) | Жидкая стойкая композиция, которая содержит антитело imc-а12 | |
JP2006517944A5 (ja) | ||
UA107557C2 (xx) | Композиція антитіла офатумумабу | |
JP2009521520A5 (ja) | ||
JP2014520852A5 (ja) | ||
JP2013508315A5 (ja) | ||
JP2013510169A5 (ja) | ||
JP2005527551A5 (ja) | ||
CO6220900A2 (es) | Forma dosificadora novedosa | |
CY1112917T1 (el) | Υγρες στοματικες συνθεσεις | |
JP2007077035A5 (ja) | ||
JP2011068692A5 (ja) | ||
NO20064085L (no) | Diettsupplement med stokiometrisk spesifikt kaliummagnesiumcitrate | |
JP2009523791A5 (ja) | ||
RU2010104395A (ru) | Пероральные фармацевтические растворы, содержащие телбивудин | |
JP2011111444A5 (ja) | ||
JP2010540461A5 (ja) | ||
WO2008015695A3 (en) | Inclusion complex of olopatadine and cyclodextrin | |
JP2012504589A5 (ja) |